This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (6)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Topical treatment of cutaneous leishmaniasis (CL) still poses a challenge. Amphotericin B, a potent antileishmanial antibiotic, is commonly administered intravenously. However, because amphotericin B is highly toxic and particularly nephrotoxic when given systemically, it is usually reserved for patients whose condition fails to respond to other treatments.¹ We have recently found in a mouse model that amphotericin B administered topically as a complex either with cholesteryl sulfate or with phospholipids, in the presence of ethanol, can penetrate into the skin and cure cutaneous leishmaniasis in a localized manner using very low total drug concentrations.² The aim of the present study was to assess the efficacy of an ethanolic amphotericin B–lipid formulation in patients with CL in a prospective, placebo-controlled trial.

Patients and Methods

Inclusion Criteria

Patients who met the following criteria were enrolled in the study: 2 or more CL lesions of similar size and ulcerative stage in a similar place on the body, but . . . [Full Text of this Article]

Exclusion Criteria

Study Design

Materials

Statistics

Results

Comment


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Fluconazole for the Treatment of Cutaneous Leishmaniasis
Zvulunov et al.
NEJM 2002;347:370-371.
FULL TEXT